1st monoclonal antibody treatment for young kids, newborns authorized by FDA
The FDA has expanded its emergency authorization for Eli Lilly's monoclonal treatment for the treatment of mild to moderate COVID-19 to children under 12, including newborns, who have tested positive and are at risk for getting severely ill. This expansion also includes preventative use in young kids who may have been exposed and who are at high risk of getting severely ill.
This is the first time a monoclonal treatment has been authorized for children under 12.
-ABC News' Sasha Pezenik